Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study

References

• Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067.
   PubMed Web of Science ®Google Scholar
• Work Group on Schizophrenia. 2010. Practice guideline for the treatment of patients with schizophrenia – second edition [cited 2019 Nov 27]. Available from: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia.pdf.
   Google Scholar
• National Institute of Mental Health. Schizophrenia [cited 2019 Nov 28]. Available from: https://www.nimh.nih.gov/health/statistics/schizophrenia.shtml.
   Google Scholar
• Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–247.
   PubMed Web of Science ®Google Scholar
• Emsley R, Chiliza B, Asmal L, et al. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13:50.
   PubMed Web of Science ®Google Scholar
• Kozma C, Dirani R, Canuso C, et al. Change in employment status over 52 weeks in patients with schizophrenia: an observational study. Curr Med Res Opin. 2011;27(2):327–333.
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Siu C, Remington G, et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology. 2019;44(6):1036–1042.
   PubMed Web of Science ®Google Scholar
• Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184:346–351.
   PubMed Web of Science ®Google Scholar
• Hong J, Windmeijer F, Novick D, et al. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(5):835–841.
   PubMed Web of Science ®Google Scholar
• Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–2071.
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3):453–460.
   PubMed Web of Science ®Google Scholar
• Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43–62.
   PubMedGoogle Scholar
• Marcus SC, Zummo J, Pettit AR, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm. 2015;21(9):754–768.
   PubMed Web of Science ®Google Scholar
• Pilon D, Muser E, Lefebvre P, et al. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia. BMC Psychiatry. 2017;17(1):207.
   PubMed Web of Science ®Google Scholar
• The University of South Florida. Florida Medicaid drug therapy management program sponsored by the Florida Agency for Health Care Administration; 2020. 2019–2020 Florida Best Practice Psychotherapeutic Medication Guidelines for Adults. [cited 2020 May 6]. Available from: http://floridabhcenter.org/2019-2020-treatment-of-adult-schizophrenia.html
   Google Scholar
• US Food and Drug Administration. Prescribing Information – INVEGA SUSTENNA [cited 2019 Nov 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022264s029lbl.pdf.
   Google Scholar
• Pilon D, Tandon N, Lafeuille MH, et al. Treatment patterns, health care resource utilization, and spending in medicaid beneficiaries initiating second-generation long-acting injectable agents versus oral atypical antipsychotics. Clin Ther. 2017;39(10):1972–1985.e2.
   PubMed Web of Science ®Google Scholar
• Kamstra R, Pilon D, Lefebvre P, et al. Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics. Curr Med Res Opin. 2018;34(8):1377–1388.
   PubMed Web of Science ®Google Scholar
• Baser O, Xie L, Pesa J, et al. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. J Med Econ. 2015;18(5):357–365.
   PubMed Web of Science ®Google Scholar
• Lafeuille MH, Grittner AM, Fortier J, et al. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. Am J Health Syst Pharm. 2015;72(5):378–389.
   PubMed Web of Science ®Google Scholar
• Pilon D, Amos TB, Kamstra R, et al. Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis. Curr Med Res Opin. 2019;35(1):41–49.
   Web of Science ®Google Scholar
• Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554–561.
   PubMed Web of Science ®Google Scholar
• Alphs L, Mao L, Lynn Starr H, et al. A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia. Schizophr Res. 2016;170(2–3):259–264.
   PubMed Web of Science ®Google Scholar
• Schreiner A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1–3):393–399.
   PubMed Web of Science ®Google Scholar
• Dilla T, Ciudad A, Álvarez M. Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adherence. 2013;7:275–284.
   PubMed Web of Science ®Google Scholar
• Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv. 2003;54(4):508–516.
   PubMed Web of Science ®Google Scholar
• Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Communications in Statistics-Simulation and Computation. 2009;38(6):1228–1234.
   Web of Science ®Google Scholar
• Alvarez-Jimenez M, Priede A, Hetrick SE, et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res. 2012;139(1–3):116–128.
   PubMed Web of Science ®Google Scholar
• Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892–909.
   PubMed Web of Science ®Google Scholar